Literature DB >> 10227686

Leukodystrophy and bone marrow transplantation: role of mixed hematopoietic chimerism.

C L Kaufman1, S T Ildstad.   

Abstract

Bone Marrow Transplantation (BMT) is currently the most physiologic treatment for some types of leukodystrophies. In enzyme deficiency states, replacement of defective genes with cells carrying "normal" copies of these genes offers a natural form of gene therapy. This review will cover the various disease states which may be treated using bone marrow transplantation as well as the obstacles and advantages offered by this treatment modality. The potential for mixed hematopoietic chimerism, with reference to the advantages and disadvantages of treating various leukodystrophies, is reviewed. Finally, certain approaches which would reduce the morbidity and mortality associated with conventional BMT are discussed. If these obstacles can be overcome, BMT may offer the hope of cure to a number, but certainly not all, leukodystrophies.

Entities:  

Mesh:

Year:  1999        PMID: 10227686     DOI: 10.1023/a:1022587914079

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  75 in total

Review 1.  The future for treatment by bone marrow transplantation for adrenoleukodystrophy, metachromatic leukodystrophy, globoid cell leukodystrophy and Hurler syndrome.

Authors:  W Krivit; L A Lockman; P A Watkins; J Hirsch; E G Shapiro
Journal:  J Inherit Metab Dis       Date:  1995       Impact factor: 4.982

2.  Bone marrow transplantation in canine mucopolysaccharidosis I. Effects within the central nervous system.

Authors:  R M Shull; N E Hastings; R R Selcer; J B Jones; J R Smith; W C Cullen; G Constantopoulos
Journal:  J Clin Invest       Date:  1987-02       Impact factor: 14.808

3.  Disappearance of lysosomal storage in spleen and liver of mucopolysaccharidosis VII mice after transplantation of genetically modified bone marrow cells.

Authors:  V Maréchal; N Naffakh; O Danos; J M Heard
Journal:  Blood       Date:  1993-08-15       Impact factor: 22.113

4.  Bone marrow transplantation for late infantile metachromatic leukodystrophy: pathogenic investigation for graft rejection.

Authors:  T Nagai; T Kaneko; H Shichijou; T Karato; A Maruyama; Y Tsuchiya
Journal:  Acta Paediatr Jpn       Date:  1993-10

5.  Reversal of pathology in murine mucopolysaccharidosis type VII by somatic cell gene transfer.

Authors:  J H Wolfe; M S Sands; J E Barker; B Gwynn; L B Rowe; C A Vogler; E H Birkenmeier
Journal:  Nature       Date:  1992 Dec 24-31       Impact factor: 49.962

6.  Bone-marrow transplantation in the Maroteaux-Lamy syndrome (mucopolysaccharidosis type VI). Biochemical and clinical status 24 months after transplantation.

Authors:  W Krivit; M E Pierpont; K Ayaz; M Tsai; N K Ramsay; J H Kersey; S Weisdorf; R Sibley; D Snover; M M McGovern
Journal:  N Engl J Med       Date:  1984-12-20       Impact factor: 91.245

7.  Lethal murine graft-versus-host disease induced by donor gamma/delta expressing T cells with specificity for host nonclassical major histocompatibility complex class Ib antigens.

Authors:  B R Blazar; P A Taylor; A Panoskaltsis-Mortari; T A Barrett; J A Bluestone; D A Vallera
Journal:  Blood       Date:  1996-01-15       Impact factor: 22.113

8.  Syngeneic bone marrow transplantation reduces the hearing loss associated with murine mucopolysaccharidosis type VII.

Authors:  M S Sands; L C Erway; C Vogler; W S Sly; E H Birkenmeier
Journal:  Blood       Date:  1995-09-01       Impact factor: 22.113

9.  Syngeneic and allogeneic bone marrow engraftment after total body irradiation: dependence on dose, dose rate, and fractionation.

Authors:  J D Down; N J Tarbell; H D Thames; P M Mauch
Journal:  Blood       Date:  1991-02-01       Impact factor: 22.113

Review 10.  Microglia: the effector cell for reconstitution of the central nervous system following bone marrow transplantation for lysosomal and peroxisomal storage diseases.

Authors:  W Krivit; J H Sung; E G Shapiro; L A Lockman
Journal:  Cell Transplant       Date:  1995 Jul-Aug       Impact factor: 4.139

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.